Vesugen Injectable
Vesugen 20 mg contains the Lys-Glu-Asp (KED) tripeptide, a synthetic bioregulator developed by Russian researcher Vladimir Khavinson and formally indexed in the NIH MeSH database as lysyl-glutamyl-aspartic acid. It belongs to the Khavinson short peptide class, which is investigated for proposed epigenetic mechanisms involving direct interaction with DNA and modulation of gene expression in vascular tissues.
In research contexts, Vesugen is studied for its potential effects on vascular endothelial cells. A 2015 study published in Advances in Gerontology reported that the vasoprotective effect of Vesugen observed in elderly patients may be mediated through epigenetic regulation of Ki-67 gene expression in endothelial cells. A 2014 clinical trial in patients with lower limb chronic arterial insufficiency found that Vesugen monotherapy significantly improved penile arterial blood flow. Another study found that Vesugen enhanced proliferation potential of immune cells in the pineal gland.
In bodybuilding and cardiovascular health contexts, Vesugen is referenced anecdotally for supporting vascular function and circulation. However, all published research originates from a single Russian research program, no independent Western replication exists, and no FDA-approved human product is available. Community dosing protocols are extrapolated from Russian-language sources and vendor reports, not from controlled Western trials. Such use falls outside any approved indication.
Research Properties of Vesugen 20 mg
- Lys-Glu-Asp (KED) tripeptide sequence indexed in NIH MeSH
- Proposed epigenetic regulation of endothelial cell proliferation
- Investigated for vascular effects in elderly patients
- Lyophilized powder format for extended stability
- 20 mg per vial for research applications
Lys-Glu-Asp Tripeptide Bioregulator
Vesugen belongs to the Khavinson bioregulator class, a family of ultrashort peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology for proposed tissue-specific regulatory effects. The Lys-Glu-Asp sequence is specifically associated with vascular tissue in this research framework.
The proposed mechanism involves direct interaction with DNA and core histones after cellular penetration. Khavinson peptides are thought to bind to specific promoter regions, modulating chromatin accessibility and enabling transcription of genes associated with tissue homeostasis. A 2015 study proposed that Vesugen's vasoprotective effect may be manifested through epigenetic regulation of the Ki-67 gene, a marker of cellular proliferation.
Research has investigated Vesugen's effects on vascular endothelial cells. One study found that Vesugen stimulated differentiation factor expression in fibroblasts, with more pronounced effects in aged cultures. A clinical trial in patients with lower limb arterial insufficiency reported improved penile arterial blood flow after Vesugen monotherapy.
Defining Characteristic
Proposed Epigenetic Mechanism
Vesugen is proposed to act through direct DNA interaction and gene expression modulation rather than cell-surface receptor binding. This epigenetic mechanism differs fundamentally from conventional cardiovascular medications.
Vesugen 20 mg vs Other Dragon Pharma Preparations
Dragon Pharma offers several Khavinson bioregulators with different tissue targets. Cardiogen is the AED tripeptide targeting cardiac tissue. Bronchogen is the AEDL tetrapeptide for bronchial epithelium. Testagen is the KEDG tetrapeptide investigated for endocrine regulation. Vesugen's KED sequence is specifically directed toward vascular endothelium.
Typical Dosage Ranges
Common reference ranges for Vesugen are derived primarily from Russian bioregulator protocols and community practices rather than controlled clinical trials. The only PubMed-anchored dose is from a mouse model using 400 mcg/kg/day intraperitoneally. Community-reported subcutaneous protocols reference 1–2 mg per injection daily for 10–20 day cycles. No dose-response studies have been conducted in humans.
| Use Case |
Common Reference Range |
Frequency |
| Preclinical (mouse model) |
400 mcg/kg (intraperitoneal) |
Daily, 2–4 months of age |
| Community protocol (subcutaneous) |
1–2 mg |
Daily for 10–20 days |
| Russian clinic (oral) |
Low microgram/kg range |
Sublingual, 10–20 day courses |
Reconstitution & Handling
Vesugen 20 mg is supplied as a lyophilized powder requiring reconstitution. Bacteriostatic Water is commonly referenced for reconstituting research peptides. A 20 mg vial reconstituted with 2 mL yields a concentration of 10 mg/mL. Store lyophilized powder refrigerated (2–8°C) for long-term storage. Reconstituted solution should be refrigerated and used within 14–28 days per general short-peptide guidance.
Stacking & Research Considerations
In Khavinson bioregulator protocols, Vesugen is sometimes referenced alongside other tissue-specific peptides. Vesilute is the Glu-Asp dipeptide targeting bladder and urogenital tissue. Cardiogen (cardiac tissue) is the most commonly mentioned companion in cardiovascular research contexts. However, no controlled studies have examined the safety or efficacy of these combinations.
Important
Individual Response Varies
The information above is for educational reference and does not constitute medical advice. Vesugen has not been evaluated by the FDA for safety or efficacy in humans.
Important Safety Information
No formal safety data exists for Vesugen from Western regulatory authorities. All published research originates from a single Russian research program, and no independent Western replication or controlled human trials have been conducted. Pharmacokinetics, bioavailability, and optimal dosing in humans are completely uncharacterized.
Important
Non-Medical Use
Non-medical use of Vesugen falls outside any approved indication. Product purity does not establish that non-medical use is safe or appropriate for an individual. Material sold online is research-chemical grade, not pharmaceutical grade.
Potential Adverse Effects
Because Vesugen is proposed to interact with DNA and modulate gene expression, theoretical risks include unintended effects on cellular regulation. No systematic human safety data are available to characterize common or rare adverse effects. Contraindications reported by community sources include pregnancy, breastfeeding, active cancer (theoretical concern due to gene regulation and cell proliferation), and individuals under 18.
Conditions Requiring Medical Evaluation
Individuals with active cancer, diagnosed cardiovascular disease, or known hypersensitivity to peptide products should exercise particular caution. No formal contraindication list exists for Vesugen because it has not undergone Western regulatory review.
Monitoring Considerations
If Vesugen is used in any research context, monitoring of cardiovascular parameters may be considered, though no standardized protocol exists. Community sources recommend monitoring blood pressure during use and consulting a physician before adjusting any prescribed medications. Laboratory testing of the product itself is separate from clinical monitoring of the individual.
Product Care
Storage & Handling
Store lyophilized powder refrigerated (2–8°C) for long-term storage, protected from light and moisture. Reconstituted solution should be refrigerated and used within 14–28 days. Do not freeze reconstituted solution. Discard if solution becomes cloudy or develops particulate matter.
Keep all research peptides and injectable products out of the reach of children.
Further Safety Information
USA Domestic 3–5 business days
International 10–15 business days
Order Processing 24–48 business hours
Tracking Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with no external product details. Products are supplied through the official Dragon Pharma distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is available
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your Vesugen 20 mg product, use the security code on the vial label and cross-check it on the official Dragon Pharma site. Verify that the labelled sequence is Lys-Glu-Asp (KED) before purchase. Original packaging and batch documentation help reinforce product legitimacy.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Recommended Conditions
Store lyophilized powder refrigerated (2–8°C) for long-term storage, protected from light and moisture. The unopened vial should be kept under conditions that preserve the peptide's structural integrity until reconstitution.
Once reconstituted, Vesugen solution should be stored at 2–8°C and used within 14–28 days. Do not freeze reconstituted solution. Discard if solution becomes cloudy or develops particulate matter.
Keep out of reach of children. Follow proper handling practices for research peptides and use appropriate sterile technique during reconstitution.
Quick Reference
Do & Don't
- Do store lyophilized powder refrigerated (2–8°C)
- Do protect from light and moisture
- Do use reconstituted solution within 14–28 days
- Don't freeze reconstituted solution
- Don't expose to excessive heat
- Don't use if powder appears discolored
What is Vesugen 20 mg used for?
Vesugen 20 mg is a research peptide supplied as a lyophilized powder. It contains the Lys-Glu-Asp tripeptide, which is investigated for proposed epigenetic effects on vascular endothelial gene expression. There is no FDA-approved human indication for Vesugen.
How often should Vesugen 20 mg be administered?
Common reference ranges for Vesugen are derived from Russian bioregulator protocols and community practices. Community-reported subcutaneous protocols reference 1–2 mg daily for 10–20 day cycles. No validated human dosing protocol exists.
Does Vesugen 20 mg require PCT?
Vesugen is not an anabolic steroid and does not suppress endogenous testosterone production. Post-cycle therapy designed for steroid cycles is not applicable. Its proposed epigenetic mechanism is distinct from hormonal suppression.
What does Vesugen do?
Vesugen is proposed to penetrate cell nuclei and interact with DNA to modulate gene expression in vascular tissues. A 2015 study proposed that its vasoprotective effect may be mediated through epigenetic regulation of the Ki-67 gene in endothelial cells. These mechanisms remain investigational and have not been independently validated.
How long does Vesugen take to work?
No established onset timeline exists for Vesugen in humans because no controlled trials have been completed. Its proposed epigenetic mechanism would theoretically involve gene expression changes that develop over days to weeks.
Is Vesugen the best vascular peptide?
No single vascular peptide is universally superior. Vesugen's research focus on vascular endothelium is distinct from other peptides in Dragon Pharma's catalog. It has been indexed in NIH MeSH and studied in a small clinical trial, but lacks independent Western validation.
What is the difference between Vesugen and Cardiogen?
Vesugen (KED) and Cardiogen (AED) are both Khavinson bioregulators but have different amino acid sequences and proposed tissue targets. Vesugen is associated with vascular endothelium, while Cardiogen targets cardiac tissue.
What is the difference between Vesugen and Vesilute?
Vesugen (KED) and Vesilute (Glu-Asp) are both Khavinson bioregulators but differ in sequence and proposed targets. Vesugen is associated with vascular endothelium, while Vesilute targets bladder and urogenital tissue.
Is 20 mg of Vesugen a lot?
20 mg is the total labeled content of the Vesugen 20 mg vial. Because no standardized human dosage exists for this research peptide, the milligram amount cannot be classified as high or low relative to established protocols. Community protocols reference doses in the 1–2 mg range per injection.
What strength is Vesugen 20 mg?
Vesugen 20 mg by Dragon Pharma contains 20 mg of Vesugen per vial as a lyophilized powder. The vial size is 2 mL. This is a research presentation.
Can Vesugen be stacked with other peptides?
In Khavinson bioregulator protocols, Vesugen is sometimes referenced alongside other tissue-specific peptides. Cardiogen and Vesilute are the most commonly mentioned companions. However, no controlled studies have examined these combinations.
No reviews found
Please log in to write Vesugen 20 mg review.
